Loading…
Balchem Corporation develops, manufactures, and distributes specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment offers specialty vitamin K2; microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; methylsulfonylmethane; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment distributes ethylene oxide and ammonia primarily for use in the health care industry; and single use canisters for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. It sells its products through sales force, independent distributors, and sales agents. The company was incorporated in 1967 and is headquartered in Montvale, New Jersey.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $1.0B | $255M | $155M | $173M | 12.3% | 8.8% | 20.5% |
| 2024 | $954M | $231M | $128M | $146M | 11.2% | 3.4% | 18.4% |
| 2023 | $922M | $215M | $109M | $146M | 10.3% | -2.1% | 3.0% |
| 2022 | $942M | $196M | $105M | $89M | 11.2% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 942.36 | 922.44 | 953.68 | 1,037.16 |
| Operating Revenue | - | 942.36 | 922.44 | 953.68 | 1,037.16 |
| Cost Of Revenue | - | 661.91 | 620.38 | 617.48 | 666.53 |
| Gross Profit | - | 280.45 | 302.06 | 336.21 | 370.63 |
| Operating Expense | - | 135.26 | 142.86 | 153.30 | 161.31 |
| Research And Development | - | 12.19 | 15.05 | 16.79 | 18.51 |
| Selling General And Administration | - | 123.07 | 127.81 | 136.50 | 142.80 |
| Total Expenses | - | 797.17 | 763.25 | 770.78 | 827.84 |
| Operating Income | - | 145.19 | 159.19 | 182.91 | 209.33 |
| Total Operating Income As Reported | - | 145.19 | 159.19 | 182.91 | 209.33 |
| EBITDA | - | 195.86 | 214.81 | 230.95 | 254.94 |
| Normalized EBITDA | - | 195.86 | 214.81 | 230.95 | 254.94 |
| EBIT | - | 144.02 | 159.87 | 182.98 | 209.25 |
| Interest Expense | - | 10.27 | 22.61 | 16.53 | 10.22 |
| Net Interest Income | - | -10.27 | -22.61 | -16.53 | -10.22 |
| Other Non Operating Income Expenses | - | -1.17 | 0.68 | 0.07 | -0.08 |
| Other Income Expense | - | -1.17 | 0.68 | 0.07 | -0.08 |
| Interest Expense Non Operating | - | 10.27 | 22.61 | 16.53 | 10.22 |
| Net Non Operating Interest Income Expense | - | -10.27 | -22.61 | -16.53 | -10.22 |
| Pretax Income | - | 133.75 | 137.26 | 166.45 | 199.03 |
| Tax Provision | - | 28.38 | 28.72 | 37.98 | 44.18 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | 105.37 | 108.54 | 128.48 | 154.84 |
| Net Income From Continuing And Discontinued Operation | - | 105.37 | 108.54 | 128.48 | 154.84 |
| Net Income From Continuing Operation Net Minority Interest | - | 105.37 | 108.54 | 128.48 | 154.84 |
| Net Income | - | 105.37 | 108.54 | 128.48 | 154.84 |
| Net Income Common Stockholders | - | 105.37 | 108.54 | 128.48 | 154.84 |
| Net Income Including Noncontrolling Interests | - | 105.37 | 108.54 | 128.48 | 154.84 |
| Normalized Income | - | 105.37 | 108.54 | 128.48 | 154.84 |
| Diluted NI Availto Com Stockholders | - | 105.37 | 108.54 | 128.48 | 154.84 |
| Basic Average Shares | - | 32.15 | 32.25 | 32.53 | 32.06 |
| Diluted Average Shares | - | 32.39 | 32.45 | 32.72 | 32.60 |
| Reconciled Depreciation | - | 51.85 | 54.94 | 47.97 | 45.69 |
| Reconciled Cost Of Revenue | - | 661.91 | 620.38 | 617.48 | 666.53 |
| General And Administrative Expense | - | 55.66 | 53.42 | 67.59 | 67.42 |
| Other Gand A | - | 55.66 | 53.42 | 67.59 | 67.42 |
| Selling And Marketing Expense | - | 67.41 | 74.40 | 68.92 | 75.37 |
Basic Materials sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Balchem Corporationthis co. | BCPC | $5.1B | 32.79↓ discount | 4.04 | 12.3% | 20.33 |
| Century Aluminum Company | CENX | $6.6B | 157.29 | 8.16 | 5.2% | 49.15 |
| Celanese Corporation | CE | $5.9B | -5.08 | 1.46 | -28.8% | 65.88 |
| Warrior Met Coal, Inc. | HCC | $5.6B | 98.13 | 2.61 | 2.7% | 22.01 |
| Sensient Technologies Corporation | SXT | $4.8B |
| - |
| - |
| - |
| - |
| - |
| 35.70 |
| 4.02 |
| 11.3% |
| 20.41 |
| Materion Corporation | MTRN | $4.7B | 63.23 | 5.02 | 7.9% | 28.96 |
| H.B. Fuller Company | FUL | $3.3B | 21.64 | 1.64 | 7.6% | 9.98 |
| The Chemours Company | CC | $3.3B | - | 13.03 | -154.4% | 21.03 |
| Hawkins, Inc. | HWKN | $3.2B | 39.04 | 5.96 | 15.3% | 19.62 |
| Peer Median | - | 39.04 | 4.52 | 6.4% | 21.52 | |